Nipruss (Sodium Nitroprusside Dihydrate)

Sodium nitroprusside releases nitric oxide when infused into the bloodstream. The nitric oxide activates soluble guanylate cyclase, raising cyclic GMP levels in vascular smooth‑muscle cells, which leads to relaxation of both arteries and veins, causing a swift reduction in preload, afterload, and arterial pressure.

The dosing of Nipruss is individualized and set by the prescribing clinician. It is administered as a continuous intravenous infusion, with the rate titrated to achieve the desired blood‑pressure target while monitoring the patient’s hemodynamic response.

Nipruss is classified as Pregnancy Category C, indicating that risk to the fetus cannot be ruled out. It should only be used when the potential maternal benefit justifies the potential risk. Limited data are available for breastfeeding, so caution is advised and a risk‑benefit assessment should be performed.

To order Nipruss, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative to sodium nitroprusside is nitroglycerin, another vasodilator. While both lower blood pressure, nitroprusside offers more rapid and controllable arterial and venous dilation, making it preferred for precise hypotension in surgery. However, nitroprusside carries a risk of cyanide toxicity, which is not a concern with nitroglycerin.

Nipruss should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The vial should be kept in its original packaging until use to maintain stability and potency.

Nipruss is given as an intravenous infusion. The solution is diluted in a compatible carrier fluid and administered through a calibrated infusion pump, allowing precise control of the infusion rate based on continuous blood‑pressure monitoring.

The most serious risks include cyanide toxicity, severe hypotension, methemoglobinemia, and cardiac arrhythmias. Clinicians should monitor blood‑pressure trends, arterial blood gases, and cyanide levels, and have antidotes such as sodium thiosulfate readily available.

Nipruss is contraindicated in patients with known hypersensitivity to sodium nitroprusside, severe anemia, significant renal impairment without adequate cyanide‑detoxifying capacity, and in those with uncontrolled shock where further vasodilation could be harmful.